Mercado global de tratamientos para la demencia, por tipo ( demencia por enfermedad de Alzheimer , demencia vascular, demencia con cuerpos de Lewy (DCL), demencia por enfermedad de Parkinson, demencia mixta, demencia frontotemporal, otras), clase de fármaco (inhibidores de la MAO, inhibidores del glutamato, inhibidores de la colinesterasa, otros), tipo de terapia (terapia de estimulación cognitiva, terapia cognitivo-conductual [TCC]), vía de administración (oral, parenteral), por usuario final (hospitales, atención domiciliaria, clínicas especializadas, otros), canal de distribución (farmacias hospitalarias, farmacias en línea, farmacias minoristas), tendencias de la industria y pronóstico hasta 2029.
Análisis y perspectivas del mercado
La demencia es una amplia categoría de enfermedades mentales que, a largo plazo, deterioran la capacidad de pensar y recordar. A pesar de los avances científicos y médicos, aún no se han identificado sus causas. Por ello, el tratamiento de la enfermedad solo se basa en los síntomas. No obstante, se sabe que trastornos del movimiento como el párkinson son un desencadenante de la demencia en muchos casos.
- El tratamiento para la demencia es de apoyo y tiene como objetivo reducir la gravedad de los síntomas. Data Bridge Market Research analiza que el mercado de tratamientos para la demencia crecerá a una tasa de crecimiento anual compuesta (TCAC) del 8,50 % durante el período de pronóstico de 2022 a 2029.
Dinámica del mercado del tratamiento de la demencia
Conductores
- Creciente envejecimiento de la población, así como el aumento de la infraestructura sanitaria
La alta prevalencia de la demencia impulsa el crecimiento del mercado de su tratamiento. Los avances en el tratamiento y el desarrollo de nuevas terapias también contribuirán a dicho crecimiento. Además, el envejecimiento vulnerable de la población puede considerarse un indicador positivo para el crecimiento de este mercado. Este crecimiento se atribuye, además, a los incentivos y beneficios gubernamentales mediante designaciones especiales. Aumento de la inversión en infraestructura sanitaria.
Accelerated technological advancements in drug discovery techniques and high government investment in drug development are factors that present new pathways in the industry.
Opportunities
- Rise in the investment for R&D by public and private organizations
Furthermore, rising R&D activities in disease-modifying drugs, as well as an increase in investment by key players in clinical studies of advanced treatment options, are expected to propel the dementia associated with Alzheimer's disease market during the forecast period.
Restraints/Challenges
However, strict government regulations governing product approval and the high costs associated with Research and development activities are expected to impede market growth.
This Dementia treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on Dementia treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
According to Alzheimer's Disease International, there will be more than 50 million people with dementia worldwide by 2020. This figure is expected to more than double every 20 years, reaching 82 million in 2030 and 152 million in 2050.
According to the National Clinical Trials (NCT) Registry, Eli Lilly and Company is conducting a phase III clinical trial in participants with early Alzheimer's disease to evaluate the safety and efficacy of donanemab. The trial began in June 2020 and is scheduled to end in December 2023.
Dementia treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Covid-19 Impact on Dementia Treatment Market
The COVID-19 pandemic outbreak is expected to have a significant impact on the Dementia drugs market. Dementia patients are at a high risk of contracting COVID-19 infection because their cognitive symptoms make it difficult to follow the safety guidelines proposed to control viral spread. Furthermore, older populations with dementia are more likely to have more severe disease consequences than younger populations without dementia. However, the COVID-19 pandemic is expected to harm new product launches, which are expected to be the most important factor in market growth.
Recent Development
- In January 2021, LSP, the leading European life sciences investor, and Professor Philip Scheltens, a world-renowned dementia scientist, will launch the LSP Dementia Fund, a fund dedicated to fighting neurodegenerative diseases, in Amsterdam.
- Alzheimer's Disease International, in collaboration with the Global Coalition on Aging (GCOA) and the Lien Foundation, will launch the third Dementia Innovation Readiness Index in 30 global cities around the world in October 2020.
Global Dementia Treatment Market Scope
The Dementia treatment market is segmented on the basis of types, drug class, therapy type, route of administration, end-users and distribution channel.. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Alzheimer's Disease Dementia
- Vascular Dementia
- Dementia With Lewy Bodies (Dlb)
- Parkinson's Disease Dementia
- Mixed Dementia
- Frontotemporal Dementia
On the basis of types, the dementia treatment market is segmented into alzheimer's disease dementia, vascular dementia, dementia with lewy bodies (DLB), parkinson's disease dementia, mixed dementia, frontotemporal dementia, others.
Drug Class
- MAO Inhibitors
- Glutamate Inhibitors
- Cholinesterase Inhibitors
- Others
The drug class segment for dementia treatment market includes MAO inhibitors, glutamate inhibitors, cholinesterase inhibitors and others.
Therapy type
- Cognitive Stimulation Therapy
- Cognitive Behavioral Therapy (CBT)
On the basis of therapy type, dementia treatment market is segmented into cognitive stimulation therapy, and cognitive behavioral therapy (CBT)).
Route of Administration
- Oral
- Parenteral
On the basis of route of administration, the Dementia treatment market is segmented into oral and parenteral
End Use
- Clinic
- Hospital
- Others
On the basis of end-users, the Dementia treatment market is segmented into clinic, hospital and others.
Distribution Channel
- Hospital Pharmacy
- Special clinics
- Others
The Dementia treatment market is also segmented on the basis of distribution channel into hospital pharmacy, special clinics and others
Pipeline Analysis
The pipeline analysis of anticonvulsant drugs includes various pipeline therapies such as LP352, OPC-214870, Ganaxolone, CT-010, Vatiquinone E-2730, XEN496, and NBI 827104. Otsuka Pharmaceutical Co. Ltd, Marinus Pharmaceuticals, Cerebral Therapeutics LLC, PTC Therapeutics, Xenon Pharmaceuticals, Longboard Pharmaceuticals, Eisai, Neurocrine Biosciences and others are the involved in the development of potential drugs for the improvement of treatment of seizures.
Dementia Treatment Market Regional Analysis/Insights
The Dementia treatment market is analysed and market size insights and trends are provided by country, types, drug class, therapy type, route of administration, end-users and distribution channel. as referenced above.
The countries covered in the Dementia treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America was the leading revenue contributor to the dementia treatment market due to the increasing incidence of dementia and the presence of key players in the same geography, whereas Asia-Pacific is expected to maintain significant growth due to increased dementia awareness programmes and the availability of effective drugs in this region.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Dementia Treatment Market Share Analysis
The Dementia treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Dementia treatment market.
Some of the major players operating in the Dementia treatment market are Eisai Co., Ltd., Novartis AG, Cipla Inc, Aurobindo Pharma, Sun Pharmaceutical Industries Ltd, Mylan N.V., Dr. Reddy’s Laboratories Ltd, Zydus Cadila, LUPIN, Torrent Pharmaceuticals Ltd, Jubilant Life Sciences Ltd, Alembic Pharmaceuticals Limited, Teva Pharmaceutical Industries Ltd, Amneal Pharmaceuticals LLC, Johnson & Johnson Services, Inc, Hikma Pharmaceuticals PLC, Allergan, Lannett and others.
SKU-
Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo
- Panel de análisis de datos interactivo
- Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
- Acceso de analista de investigación para personalización y consultas
- Análisis de la competencia con panel interactivo
- Últimas noticias, actualizaciones y análisis de tendencias
- Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Tabla de contenido
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL DEMENTIA TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL DEMENTIA TREATMENT MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 EPIDEMIOLOGY MODELING
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL DEMENTIA TREATMENT MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER'S 5 FORCES
4.2 PESTEL ANALYSIS
5 EPIDEMIOLOGY
5.1 INCIDENCE OF ALL BY GENDER
5.1.1 PREVALENCE OF DEMENTIA
5.2 TREATMENT RATE
5.3 MORTALITY RATE
5.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
5.5 PATEINT TREATMENT SUCCESS RATES
6 INDUSTRY INSIGHTS
6.1 PATENT ANALYSIS
6.2 DRUG TREATMENT RATE BY MATURED MARKETS
6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
6.4 PATIENT FLOW DIAGRAM
6.5 KEY PRICING STRATEGIES
6.6 KEY PATIENT ENROLLMENT STRATEGIES
6.7 INTERVIEWS WITH NEUROLOGIST
6.8 INTERVIEWS WITH GENETICS SPECIALIST
6.9 OTHER KOL SNAPSHOTS
7 REGULATORY SCENARIO
7.1 FDA APPROVALS
7.2 EMA APPROVALS
8 MERGERS AND ACQUISITION
8.1 LICENSING
8.2 COMMERCIALIZATION AGREEMENTS
9 PIPELINE ANALYSIS
9.1 CLINICAL TRIALS AND PHASE ANALYSIS
9.2 DRUG THERAPY PIPELINE
9.3 PHASE III CANDIDATES
9.3.1 AGB101
9.3.1.1. ATUZAGINSTAT
9.3.1.2. AVP-786
9.3.1.3. AXS-05
9.3.1.4. AXS-05
9.3.1.5. BLARCAMESINE (ANAVEX2-73)
9.3.1.6. BREXPIPRAZOLE
9.3.1.7. DONANEMAB
9.3.1.8. ESCITALOPRAM
9.3.1.9. GANTENERUMAB
9.3.1.10. TRX0237
9.3.1.11. OTHERS
9.4 PHASE II CANDIDATES
9.4.1 ABVAC40
9.4.2 ACL-35
9.4.3 BARCITINIB
9.4.4 BAPRENEMAB
9.4.5 DAPAGLIFLOZIN
9.4.6 DARATUMUMAB
9.4.7 DRONABINOL
9.4.8 LECANEMAB
9.4.9 L-SERINE
9.4.10 LUPRON
9.4.11 OTHERS
9.5 PHASE I CANDIDATES
9.6 OTHERS (PRE-CLINICAL AND RESEARCH)
10 MARKET OVERVIEW
10.1 DRIVERS
10.2 RESTRAINS
10.3 OPPURTUNITY
10.4 CHALLENGES
11 GLOBAL DEMENTIA TREATMENT MARKET, BY TREATMENT
11.1 OVERVIEW
11.2 MEDICATION
11.2.1 CHOLINESTERASE INHIBITORS
11.2.1.1. BY DRUGS
11.2.1.1.1. DONEPEZIL
11.2.1.1.1.1 MARKET VALUE (USD MN)
11.2.1.1.1.2 MARKET VOLUME (IU)
11.2.1.1.1.3 AVERAGE SELLING PRICE (USD)
11.2.1.1.2. RIVASTIGMINE
11.2.1.1.2.1 MARKET VALUE (USD MN)
11.2.1.1.2.2 MARKET VOLUME (IU)
11.2.1.1.2.3 AVERAGE SELLING PRICE (USD)
11.2.1.1.3. GALANTAMINE
11.2.1.1.3.1 MARKET VALUE (USD MN)
11.2.1.1.3.2 MARKET VOLUME (IU)
11.2.1.1.3.3 AVERAGE SELLING PRICE (USD)
11.2.1.1.4. OTHERS
11.2.1.2. BY DRUG TYPE
11.2.1.2.1. GENERICS
11.2.1.2.2. BRANDED
11.2.1.2.2.1 ARICEPT
11.2.1.2.2.1.1. MARKET VALUE (USD MN)
11.2.1.2.2.1.2. MARKET VOLUME (IU)
11.2.1.2.2.1.3. AVERAGE SELLING PRICE (USD)
11.2.1.2.2.2 EXELON
11.2.1.2.2.2.1. MARKET VALUE (USD MN)
11.2.1.2.2.2.2. MARKET VOLUME (IU)
11.2.1.2.2.2.3. AVERAGE SELLING PRICE (USD)
11.2.1.2.2.3 RAZADYNE
11.2.1.2.2.3.1. MARKET VALUE (USD MN)
11.2.1.2.2.3.2. MARKET VOLUME (IU)
11.2.1.2.2.3.3. AVERAGE SELLING PRICE (USD)
11.2.1.2.2.4 OTHERS
11.2.2 NMDA ANTAGONIST (MEMANTINE)
11.2.2.1. MARKET VALUE (USD MN)
11.2.2.2. MARKET VOLUME (IU)
11.2.2.3. AVERAGE SELLING PRICE (USD)
11.2.3 ADUCANUMAB
11.2.3.1. MARKET VALUE (USD MN)
11.2.3.2. MARKET VOLUME (IU)
11.2.3.3. AVERAGE SELLING PRICE (USD)
11.2.4 ANXIOLYTICS
11.2.4.1. BY DRUGS
11.2.4.1.1. LORAZEPAM
11.2.4.1.1.1 MARKET VALUE (USD MN)
11.2.4.1.1.2 MARKET VOLUME (IU)
11.2.4.1.1.3 AVERAGE SELLING PRICE (USD)
11.2.4.1.2. OXAZEPAM
11.2.4.1.2.1 MARKET VALUE (USD MN)
11.2.4.1.2.2 MARKET VOLUME (IU)
11.2.4.1.2.3 AVERAGE SELLING PRICE (USD)
11.2.4.1.3. OTHERS
11.2.4.2. BY DRUG TYPE
11.2.4.2.1. GENERICS
11.2.4.2.2. BRANDED
11.2.4.2.2.1 TRAPEX
11.2.4.2.2.1.1. MARKET VALUE (USD MN)
11.2.4.2.2.1.2. MARKET VOLUME (IU)
11.2.4.2.2.1.3. AVERAGE SELLING PRICE (USD)
11.2.4.2.2.2 SERAX
11.2.4.2.2.2.1. MARKET VALUE (USD MN)
11.2.4.2.2.2.2. MARKET VOLUME (IU)
11.2.4.2.2.2.3. AVERAGE SELLING PRICE (USD)
11.2.4.2.2.3 OTHERS
11.2.5 ANTIDEPRESSANT
11.2.5.1. BY DRUGS
11.2.5.1.1. CITALOPRAM
11.2.5.1.1.1 MARKET VALUE (USD MN)
11.2.5.1.1.2 MARKET VOLUME (IU)
11.2.5.1.1.3 AVERAGE SELLING PRICE (USD)
11.2.5.1.2. PAROXETINE
11.2.5.1.2.1 MARKET VALUE (USD MN)
11.2.5.1.2.2 MARKET VOLUME (IU)
11.2.5.1.2.3 AVERAGE SELLING PRICE (USD)
11.2.5.1.3. ESCITALOPRAM
11.2.5.1.3.1 MARKET VALUE (USD MN)
11.2.5.1.3.2 MARKET VOLUME (IU)
11.2.5.1.3.3 AVERAGE SELLING PRICE (USD)
11.2.5.1.4. MIRTAZAPINE
11.2.5.1.4.1 MARKET VALUE (USD MN)
11.2.5.1.4.2 MARKET VOLUME (IU)
11.2.5.1.4.3 AVERAGE SELLING PRICE (USD)
11.2.5.1.5. TRAZODONE
11.2.5.1.5.1 MARKET VALUE (USD MN)
11.2.5.1.5.2 MARKET VOLUME (IU)
11.2.5.1.5.3 AVERAGE SELLING PRICE (USD)
11.2.5.1.6. OTHERS
11.2.5.2. BY DRUG TYPE
11.2.5.2.1. GENERICS
11.2.5.2.2. BRANDED
11.2.5.2.2.1 AKARIN
11.2.5.2.2.1.1. MARKET VALUE (USD MN)
11.2.5.2.2.1.2. MARKET VOLUME (IU)
11.2.5.2.2.1.3. AVERAGE SELLING PRICE (USD)
11.2.5.2.2.2 PAXIL
11.2.5.2.2.2.1. MARKET VALUE (USD MN)
11.2.5.2.2.2.2. MARKET VOLUME (IU)
11.2.5.2.2.2.3. AVERAGE SELLING PRICE (USD)
11.2.5.2.2.3 LEXAPRO
11.2.5.2.2.3.1. MARKET VALUE (USD MN)
11.2.5.2.2.3.2. MARKET VOLUME (IU)
11.2.5.2.2.3.3. AVERAGE SELLING PRICE (USD)
11.2.5.2.2.4 REMERON
11.2.5.2.2.4.1. MARKET VALUE (USD MN)
11.2.5.2.2.4.2. MARKET VOLUME (IU)
11.2.5.2.2.4.3. AVERAGE SELLING PRICE (USD)
11.2.5.2.2.5 DESYREL
11.2.5.2.2.5.1. MARKET VALUE (USD MN)
11.2.5.2.2.5.2. MARKET VOLUME (IU)
11.2.5.2.2.5.3. AVERAGE SELLING PRICE (USD)
11.2.5.2.2.6 OTHERS
11.2.5.3. BY DRUG TYPE
11.2.5.3.1. GENERICS
11.2.5.3.2. BRANDED
11.2.5.3.2.1 CELEXA
11.2.5.3.2.1.1. MARKET VALUE (USD MN)
11.2.5.3.2.1.2. MARKET VOLUME (IU)
11.2.5.3.2.1.3. AVERAGE SELLING PRICE (USD)
11.2.5.3.2.2 AROPAX
11.2.5.3.2.2.1. MARKET VALUE (USD MN)
11.2.5.3.2.2.2. MARKET VOLUME (IU)
11.2.5.3.2.2.3. AVERAGE SELLING PRICE (USD)
11.2.5.3.2.3 LEXAPRO
11.2.5.3.2.3.1. MARKET VALUE (USD MN)
11.2.5.3.2.3.2. MARKET VOLUME (IU)
11.2.5.3.2.3.3. AVERAGE SELLING PRICE (USD)
11.2.5.3.2.4 MIRATAZ
11.2.5.3.2.4.1. MARKET VALUE (USD MN)
11.2.5.3.2.4.2. MARKET VOLUME (IU)
11.2.5.3.2.4.3. AVERAGE SELLING PRICE (USD)
11.2.5.3.2.5 OTHERS
11.2.6 ANTIPSYCHOTIC MEDICINES
11.2.6.1. BY DRUGS
11.2.6.1.1. ARIPIPRAZOLE
11.2.6.1.1.1 MARKET VALUE (USD MN)
11.2.6.1.1.2 MARKET VOLUME (IU)
11.2.6.1.1.3 AVERAGE SELLING PRICE (USD)
11.2.6.1.2. HALOPERIDOL
11.2.6.1.2.1 MARKET VALUE (USD MN)
11.2.6.1.2.2 MARKET VOLUME (IU)
11.2.6.1.2.3 AVERAGE SELLING PRICE (USD)
11.2.6.1.3. OLANZAPINE
11.2.6.1.3.1 MARKET VALUE (USD MN)
11.2.6.1.3.2 MARKET VOLUME (IU)
11.2.6.1.3.3 AVERAGE SELLING PRICE (USD)
11.2.6.1.4. RISPERIDONE
11.2.6.1.4.1 MARKET VALUE (USD MN)
11.2.6.1.4.2 MARKET VOLUME (IU)
11.2.6.1.4.3 AVERAGE SELLING PRICE (USD)
11.2.6.1.5. OTHERS
11.2.6.2. BY DRUG TYPE
11.2.6.2.1. GENERICS
11.2.6.2.2. BRANDED
11.2.6.2.2.1 ABILIFY
11.2.6.2.2.1.1. MARKET VALUE (USD MN)
11.2.6.2.2.1.2. MARKET VOLUME (IU)
11.2.6.2.2.1.3. AVERAGE SELLING PRICE (USD)
11.2.6.2.2.2 HALODOL
11.2.6.2.2.2.1. MARKET VALUE (USD MN)
11.2.6.2.2.2.2. MARKET VOLUME (IU)
11.2.6.2.2.2.3. AVERAGE SELLING PRICE (USD)
11.2.6.2.2.3 ZYPREXA
11.2.6.2.2.3.1. MARKET VALUE (USD MN)
11.2.6.2.2.3.2. MARKET VOLUME (IU)
11.2.6.2.2.3.3. AVERAGE SELLING PRICE (USD)
11.2.6.2.2.4 RISPERDAL
11.2.6.2.2.4.1. MARKET VALUE (USD MN)
11.2.6.2.2.4.2. MARKET VOLUME (IU)
11.2.6.2.2.4.3. AVERAGE SELLING PRICE (USD)
11.2.6.2.2.5 OTHERS
11.2.7 OTHERS
11.3 THERAPY
11.3.1 COGNITIVE STIMULATION THERAPY (CST)
11.3.2 COGNITIVE REHABILITATION
11.3.3 OTHERS
12 GLOBAL DEMENTIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
12.1 OVERVIEW
12.2 ORAL
12.2.1 SOLID ORAL DRUGS
12.2.1.1. TABLETS
12.2.1.2. CAPSULES
12.2.1.3. POWDERS
12.2.1.4. PILLS
12.2.1.5. OTHERS
12.2.2 LIQUID ORAL DRUGS
12.2.2.1. SYRUPS
12.2.2.2. SOLUTIONS
12.2.2.3. OTHERS
12.2.3 SEMI-SOLID ORAL DRUGS
12.2.3.1. GELS
12.2.3.2. EMULSIONS
12.2.3.3. ELIXIRS
12.2.3.4. OTHERS
12.3 TOPICAL
12.4 PARENTERAL
12.4.1 INTRAVENOUS
12.4.2 SUBCUTANEOUS
12.4.3 OTHERS
13 GLOBAL DEMENTIA TREATMENT MARKET, BY END USER
13.1 OVERVIEW
13.2 HOSPITALS
13.3 SPECIALTY CLINICS
13.4 HOME HEALTHCARE
13.5 OTHERS
14 GLOBAL DEMENTIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 HOSPITAL PHARMACY
14.3 RETAIL PHARMACY
14.4 ONLINE PHARMACY
14.5 OTHERS
15 GLOBAL DEMENTIA TREATMENT MARKET, BY GEOGRAPHY
GLOBAL DEMENTIA TREATMENT MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
15.1 NORTH AMERICA
15.1.1 U.S.
15.1.1.1. U.S. DEMENTIA TREATMENT MARKET, BY TREATMENT
15.1.1.2. U.S. DEMENTIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
15.1.1.3. U.S. DEMENTIA TREATMENT MARKET, BY END USER
15.1.1.4. U.S. DEMENTIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL
15.1.2 CANADA
15.1.3 MEXICO
15.1.4 DOMINICAN REPUBLIC
15.1.5 JAMAICA
15.1.6 PANAMA
15.2 EUROPE
15.2.1 GERMANY
15.2.2 FRANCE
15.2.3 U.K.
15.2.4 HUNGARY
15.2.5 LITHUANIA
15.2.6 AUSTRIA
15.2.7 IRELAND
15.2.8 NORWAY
15.2.9 POLAND
15.2.10 ITALY
15.2.11 SPAIN
15.2.12 RUSSIA
15.2.13 TURKEY
15.2.14 NETHERLANDS
15.2.15 SWITZERLAND
15.2.16 REST OF EUROPE
15.3 ASIA-PACIFIC
15.3.1 JAPAN
15.3.2 CHINA
15.3.3 TAIWAN
15.3.4 SOUTH KOREA
15.3.5 INDIA
15.3.6 AUSTRALIA
15.3.7 SINGAPORE
15.3.8 THAILAND
15.3.9 MALAYSIA
15.3.10 INDONESIA
15.3.11 PHILIPPINES
15.3.12 VIETNAM
15.3.13 REST OF ASIA-PACIFIC
15.4 SOUTH AMERICA
15.4.1 BRAZIL
15.4.2 ECUADOR
15.4.3 CHILE
15.4.4 COLOMBIA
15.4.5 VENEZUELA
15.4.6 ARGENTINA
15.4.7 PERU
15.4.8 CURAÇAO
15.4.9 PARAGUAY
15.4.10 URUGUAY
15.4.11 TRINIDAD AND TOBAGO
15.4.12 REST OF SOUTH AMERICA
15.5 MIDDLE EAST AND AFRICA
15.5.1 SOUTH AFRICA
15.5.2 SAUDI ARABIA
15.5.3 UAE
15.5.4 EGYPT
15.5.5 KUWAIT
15.5.6 ISRAEL
15.5.7 BOLIVIA
15.5.8 REST OF MIDDLE EAST AND AFRICA
15.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
16 GLOBAL DEMENTIA TREATMENT MARKET, SWOT AND DBMR ANALYSIS
17 GLOBAL DEMENTIA TREATMENT MARKET, COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: GLOBAL
17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
17.3 COMPANY SHARE ANALYSIS: EUROPE
17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
17.5 MERGERS & ACQUISITIONS
17.6 NEW PRODUCT DEVELOPMENT & APPROVALS
17.7 EXPANSIONS
17.8 REGULATORY CHANGES
17.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
18 GLOBAL DEMENTIA TREATMENT MARKET, COMPANY PROFILE
18.1 BIOGEN INC
18.1.1 COMPANY OVERVIEW
18.1.2 REVENUE ANALYSIS
18.1.3 GEOGRAPHIC PRESENCE
18.1.4 PRODUCT PORTFOLIO
18.1.5 RECENT DEVELOPMENTS
18.2 EISAI CO. LTD.
18.2.1 COMPANY OVERVIEW
18.2.2 REVENUE ANALYSIS
18.2.3 GEOGRAPHIC PRESENCE
18.2.4 PRODUCT PORTFOLIO
18.2.5 RECENT DEVELOPMENTS
18.3 NOVARTIS AG
18.3.1 COMPANY OVERVIEW
18.3.2 REVENUE ANALYSIS
18.3.3 GEOGRAPHIC PRESENCE
18.3.4 PRODUCT PORTFOLIO
18.3.5 RECENT DEVELOPEMENTS
18.4 MERZ PHARMA
18.4.1 COMPANY OVERVIEW
18.4.2 REVENUE ANALYSIS
18.4.3 GEOGRAPHIC PRESENCE
18.4.4 PRODUCT PORTFOLIO
18.4.5 RECENT DEVELOPEMENTS
18.5 PFIZER INC.
18.5.1 COMPANY OVERVIEW
18.5.2 REVENUE ANALYSIS
18.5.3 GEOGRAPHIC PRESENCE
18.5.4 PRODUCT PORTFOLIO
18.5.5 RECENT DEVELOPEMENTS
18.6 JOHNSON & JOHNSON SERVICES
18.6.1 COMPANY OVERVIEW
18.6.2 REVENUE ANALYSIS
18.6.3 GEOGRAPHIC PRESENCE
18.6.4 PRODUCT PORTFOLIO
18.6.5 RECENT DEVELOPEMENTS
18.7 H. LUNDBECK A/S
18.7.1 COMPANY OVERVIEW
18.7.2 REVENUE ANALYSIS
18.7.3 GEOGRAPHIC PRESENCE
18.7.4 PRODUCT PORTFOLIO
18.7.5 RECENT DEVELOPEMENTS
18.8 ABBVIE INC.
18.8.1 COMPANY OVERVIEW
18.8.2 REVENUE ANALYSIS
18.8.3 GEOGRAPHIC PRESENCE
18.8.4 PRODUCT PORTFOLIO
18.8.5 RECENT DEVELOPEMENTS
18.9 ELI LILLY AND COMPANY
18.9.1 COMPANY OVERVIEW
18.9.2 REVENUE ANALYSIS
18.9.3 GEOGRAPHIC PRESENCE
18.9.4 PRODUCT PORTFOLIO
18.9.5 RECENT DEVELOPEMENTS
18.1 ABBOTT
18.10.1 COMPANY OVERVIEW
18.10.2 REVENUE ANALYSIS
18.10.3 GEOGRAPHIC PRESENCE
18.10.4 PRODUCT PORTFOLIO
18.10.5 RECENT DEVELOPEMENTS
18.11 ASTRAZENECA
18.11.1 COMPANY OVERVIEW
18.11.2 REVENUE ANALYSIS
18.11.3 GEOGRAPHIC PRESENCE
18.11.4 PRODUCT PORTFOLIO
18.11.5 RECENT DEVELOPEMENTS
18.12 TEVA PHARMACEUTICAL INDUSTRIES LTD.
18.12.1 COMPANY OVERVIEW
18.12.2 REVENUE ANALYSIS
18.12.3 GEOGRAPHIC PRESENCE
18.12.4 PRODUCT PORTFOLIO
18.12.5 RECENT DEVELOPEMENTS
18.13 F. HOFFMANN-LA ROCHE LTD.
18.13.1 COMPANY OVERVIEW
18.13.2 REVENUE ANALYSIS
18.13.3 GEOGRAPHIC PRESENCE
18.13.4 PRODUCT PORTFOLIO
18.13.5 RECENT DEVELOPEMENTS
18.14 BRISTOL-MYERS SQUIBB COMPANY
18.14.1 COMPANY OVERVIEW
18.14.2 REVENUE ANALYSIS
18.14.3 GEOGRAPHIC PRESENCE
18.14.4 PRODUCT PORTFOLIO
18.14.5 RECENT DEVELOPMENTS
18.15 ALEMBIC USA LTD
18.15.1 COMPANY OVERVIEW
18.15.2 REVENUE ANALYSIS
18.15.3 GEOGRAPHIC PRESENCE
18.15.4 PRODUCT PORTFOLIO
18.15.5 RECENT DEVELOPMENTS
18.16 APOTEX INC.
18.16.1 COMPANY OVERVIEW
18.16.2 REVENUE ANALYSIS
18.16.3 GEOGRAPHIC PRESENCE
18.16.4 PRODUCT PORTFOLIO
18.16.5 RECENT DEVELOPMENTS
18.17 WOCKHARDT
18.17.1 COMPANY OVERVIEW
18.17.2 REVENUE ANALYSIS
18.17.3 GEOGRAPHIC PRESENCE
18.17.4 PRODUCT PORTFOLIO
18.17.5 RECENT DEVELOPMENTS
18.18 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
18.18.1 COMPANY OVERVIEW
18.18.2 REVENUE ANALYSIS
18.18.3 GEOGRAPHIC PRESENCE
18.18.4 PRODUCT PORTFOLIO
18.18.5 RECENT DEVELOPMENTS
18.19 HIKMA PHARMACEUTICALS PLC
18.19.1 COMPANY OVERVIEW
18.19.2 REVENUE ANALYSIS
18.19.3 GEOGRAPHIC PRESENCE
18.19.4 PRODUCT PORTFOLIO
18.19.5 RECENT DEVELOPMENTS
18.2 VIATRIS INC.
18.20.1 COMPANY OVERVIEW
18.20.2 REVENUE ANALYSIS
18.20.3 GEOGRAPHIC PRESENCE
18.20.4 PRODUCT PORTFOLIO
18.20.5 RECENT DEVELOPMENTS
18.21 CIPLA
18.21.1 COMPANY OVERVIEW
18.21.2 REVENUE ANALYSIS
18.21.3 GEOGRAPHIC PRESENCE
18.21.4 PRODUCT PORTFOLIO
18.21.5 RECENT DEVELOPEMENTS
18.22 OTSUKA HOLDINGS
18.22.1 COMPANY OVERVIEW
18.22.2 REVENUE ANALYSIS
18.22.3 GEOGRAPHIC PRESENCE
18.22.4 PRODUCT PORTFOLIO
18.22.5 RECENT DEVELOPEMENTS
18.23 GLAXOSMITHKLINE
18.23.1 COMPANY OVERVIEW
18.23.2 REVENUE ANALYSIS
18.23.3 GEOGRAPHIC PRESENCE
18.23.4 PRODUCT PORTFOLIO
18.23.5 RECENT DEVELOPMENTS
18.24 UCB
18.24.1 COMPANY OVERVIEW
18.24.2 REVENUE ANALYSIS
18.24.3 GEOGRAPHIC PRESENCE
18.24.4 PRODUCT PORTFOLIO
18.24.5 RECENT DEVELOPEMNTS
18.25 CADILA HEALTHCARE
18.25.1 COMPANY OVERVIEW
18.25.2 REVENUE ANALYSIS
18.25.3 GEOGRAPHIC PRESENCE
18.25.4 PRODUCT PORTFOLIO
18.25.5 RECENT DEVELOPEMNTS
18.26 BAUSCH & LOMB
18.26.1 COMPANY OVERVIEW
18.26.2 REVENUE ANALYSIS
18.26.3 GEOGRAPHIC PRESENCE
18.26.4 PRODUCT PORTFOLIO
18.26.5 RECENT DEVELOPEMNTS
18.27 GRIFOLS
18.27.1 COMPANY OVERVIEW
18.27.2 REVENUE ANALYSIS
18.27.3 GEOGRAPHIC PRESENCE
18.27.4 PRODUCT PORTFOLIO
18.27.5 RECENT DEVELOPEMNTS
18.28 SINO BIOPHARMACEUTICALS
18.28.1 COMPANY OVERVIEW
18.28.2 REVENUE ANALYSIS
18.28.3 GEOGRAPHIC PRESENCE
18.28.4 PRODUCT PORTFOLIO
18.28.5 RECENT DEVELOPEMNTS
18.29 FERRING PHARMACEUTICALS
18.29.1 COMPANY OVERVIEW
18.29.2 REVENUE ANALYSIS
18.29.3 GEOGRAPHIC PRESENCE
18.29.4 PRODUCT PORTFOLIO
18.29.5 RECENT DEVELOPEMNTS
18.3 IPSEN PHARMA
18.30.1 COMPANY OVERVIEW
18.30.2 REVENUE ANALYSIS
18.30.3 GEOGRAPHIC PRESENCE
18.30.4 PRODUCT PORTFOLIO
18.30.5 RECENT DEVELOPEMNTS
*NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
19 RELATED REPORTS
20 CONCLUSION
21 QUESTIONNAIRE
22 ABOUT DATA BRIDGE MARKET RESEARCH
Metodología de investigación
La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.
La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.
Personalización disponible
Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.
